BTL Unveils EXOLASE ONE®, a Revolutionary Fused Erbium Laser Technology in Aesthetic Medicine

Exciting Innovations in Aesthetic Medicine by BTL

In a significant stride within the medical aesthetics industry, BTL has recently established a dedicated laser division and is set to introduce EXOLASE ONE®, touted as the world’s first fused erbium laser. This innovative technology signals a major shift in laser facial rejuvenation treatments and aims to redefine the standard of care for patients.

BTL, a global frontrunner in advanced energy-based medical technologies, has a rich history in developing impactful solutions across various health sectors. Founded in 1993, the company has successfully expanded across more than 90 countries, creating a strong presence with over 5,000 employees. Known for its pioneering brands such as EMSCULPT NEO® and EMFACE®, BTL is ready to add another groundbreaking product to its portfolio.

The Game-Changing Features of EXOLASE ONE®

The EXOLASE ONE® system utilizes an advanced proprietary technology that seamlessly fuses multiple erbium laser wavelengths into a singular light beam. This innovative approach allows the system to target the same area concurrently, presenting a novel method of laser-tissue interaction that departs from traditional practices. Its unique capabilities promise enhanced clinical efficacy, faster treatment times, and improved patient comfort, addressing common challenges associated with conventional laser systems.

Dr. Reha Yavuzer, a leading clinical investigator for the platform, emphasized the system’s efficiency. He noted that the EXOLASE ONE® can treat an entire face in less than 10 minutes, delivering results that are superior to what patients might expect from existing ablative and non-ablative systems. This capacity not only streamlines the procedure but also elevates the overall patient experience.

Launch Timeline and Future Plans

Following an initial early-access program aimed at select key opinion leaders, BTL plans to commence a wider global rollout of EXOLASE ONE® in 2027. The focus will center initially on aesthetic medicine and dermatology, where the laser’s capabilities can be fully leveraged.

With the establishment of the new laser division, BTL is now organizing six key areas of expertise, complementing their established divisions in aesthetics, mental wellness, rehabilitation, cardiology, and robotics. This strategic move reinforces BTL's commitment to advancing healthcare technology and improving patient outcomes on a global scale.

BTL’s Future Perspectives

"This is a historic moment for our company," stated Tomas Schwarz, CEO of BTL Group. "From the beginning, we knew that only a genuinely disruptive technology would allow us to build a true laser powerhouse." The feedback received from clinical centers around the world acknowledges EXOLASE ONE® as that transformative innovation.

As BTL moves forward, the focus remains on developing cutting-edge technologies that enhance the efficiency and effectiveness of medical treatments across various fields. The company’s extensive research and development infrastructure has been instrumental in driving their growth and offering tailored solutions that address specific medical needs.

For anyone eager to stay informed about BTL’s advancements and the upcoming launch of EXOLASE ONE®, additional details and updates can be accessed via their official website at www.btlaesthetics.com.

With the introduction of EXOLASE ONE®, BTL not only underscores its position as a leader in the aesthetic technology market but also sets a new benchmark in laser treatment protocols for years to come.